119 related articles for article (PubMed ID: 18261369)
1. CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes.
Dragoni S; Materozzi G; Pessina F; Frosini M; Marco JL; Unzeta M; Sgaragli G; Valoti M
J Pharm Pharm Sci; 2007; 10(4):473-85. PubMed ID: 18261369
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl.
Valoti M; Fusi F; Frosini M; Pessina F; Tipton KF; Sgaragli GP
Eur J Pharmacol; 2000 Mar; 391(3):199-206. PubMed ID: 10729359
[TBL] [Abstract][Full Text] [Related]
3. l-Deprenyl metabolism by the cytochrome P450 system in monkey (Cercopithecus aethiops) liver microsomes.
Dragoni S; Bellik L; Frosini M; Sgaragli G; Marini S; Gervasi PG; Valoti M
Xenobiotica; 2003 Feb; 33(2):181-95. PubMed ID: 12623760
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species.
Bellik L; Dragoni S; Pessina F; Sanz E; Unzeta M; Valoti M
Acta Biochim Pol; 2010; 57(2):235-9. PubMed ID: 20532254
[TBL] [Abstract][Full Text] [Related]
5. Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation.
Shaik AN; LeDuc BW; Khan AA
Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):827-834. PubMed ID: 28185143
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Pérez V; Morón J; Pastó M; Unzeta M
Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
[TBL] [Abstract][Full Text] [Related]
7. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450-dependent metabolism of l-deprenyl in monkey (Cercopithecus aethiops) and C57BL/6 mouse brain microsomal preparations.
Dragoni S; Bellik L; Frosini M; Matteucci G; Sgaragli G; Valoti M
J Neurochem; 2003 Sep; 86(5):1174-80. PubMed ID: 12911625
[TBL] [Abstract][Full Text] [Related]
9. Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase in hepatic metabolism of L-775,606, a potent 5-HT(1D) receptor agonist.
Prueksaritanont T; Lu P; Gorham L; Sternfeld F; Vyas KP
Xenobiotica; 2000 Jan; 30(1):47-59. PubMed ID: 10659950
[TBL] [Abstract][Full Text] [Related]
10. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
Rodrigues AD; Mulford DJ; Lee RD; Surber BW; Kukulka MJ; Ferrero JL; Thomas SB; Shet MS; Estabrook RW
Drug Metab Dispos; 1995 Jul; 23(7):765-75. PubMed ID: 7587966
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine.
Constantino L; Paixão P; Moreira R; Portela MJ; Do Rosario VE; Iley J
Exp Toxicol Pathol; 1999 Jul; 51(4-5):299-303. PubMed ID: 10445386
[TBL] [Abstract][Full Text] [Related]
13. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells.
Sanz E; Quintana A; Battaglia V; Toninello A; Hidalgo J; Ambrosio S; Valoti M; Marco JL; Tipton KF; Unzeta M
J Neurochem; 2008 Jun; 105(6):2404-17. PubMed ID: 18331475
[TBL] [Abstract][Full Text] [Related]
14. Enantioselective 2-hydroxylation of RS-8359, a selective and reversible MAO-A inhibitor, by cytochrome P450 in mouse and rat liver microsomes.
Itoh K; Nishiya Y; Takasaki W; Adachi M; Tanaka Y
Chirality; 2006 Aug; 18(8):592-8. PubMed ID: 16642492
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
Yoshida T; Yamada Y; Yamamoto T; Kuroiwa Y
Xenobiotica; 1986 Feb; 16(2):129-36. PubMed ID: 3083608
[TBL] [Abstract][Full Text] [Related]
16. The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
Prat G; Pérez V; Rubi A; Casas M; Unzeta M
J Neural Transm (Vienna); 2000; 107(4):409-17. PubMed ID: 11215752
[TBL] [Abstract][Full Text] [Related]
17. Activation and detoxification metabolism of urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone by rat and mouse hepatic microsomes.
Stiborova M; Cechova T; Borek-Dohalska L; Moserova M; Frei E; Schmeiser HH; Paca J; Arlt VM
Neuro Endocrinol Lett; 2012; 33 Suppl 3():8-15. PubMed ID: 23353838
[TBL] [Abstract][Full Text] [Related]
18. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
Unzeta M; Sanz E
Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
[TBL] [Abstract][Full Text] [Related]
19. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide.
Zhang L; Fitzloff JF; Engel LC; Cook CS
Xenobiotica; 2001 Feb; 31(2):73-83. PubMed ID: 11407536
[TBL] [Abstract][Full Text] [Related]
20. Kinetic characteristics of norcocaine N-hydroxylation in mouse and human liver microsomes: involvement of CYP enzymes.
Pellinen P; Kulmala L; Konttila J; Auriola S; Pasanen M; Juvonen R
Arch Toxicol; 2000 Nov; 74(9):511-20. PubMed ID: 11131030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
